Successfully navigating the valley of death: the importance of accelerators to support academic drug discovery and...

Area of Science:

• Drug discovery and development
• Translational research
• Academic research

Background:

• The transition of academic research to clinical therapies faces significant hurdles, termed the 'valley of death'.
• Existing support centers and accelerators provide crucial funding and scientific aid, yet challenges persist.
• Cultural and expertise gaps, alongside funding limitations, hinder the progress of many novel therapeutic technologies.

Purpose of the Study:

• To summarize obstacles in academic drug discovery projects.
• To present potential solutions and best practices for overcoming these challenges.
• To highlight the role of accelerators, such as the Critical Path Institute's Translational Therapeutics Accelerator (TRxA), in bridging the 'valley of death'.

Main Methods:

• Meta-opinion article synthesizing existing literature.
• Review of common obstacles including funding, regulatory education, and reproducibility.
• Case study of a specific accelerator program (TRxA).

Main Results:

• The 'valley of death' is a persistent challenge in academic drug discovery.
• Funding, regulatory knowledge, reproducibility, and organizational factors are key obstacles.
• Dedicated accelerators can effectively complement traditional funding mechanisms.

Conclusions:

• The 'valley of death' in academic drug discovery is a significant but manageable obstacle.
• Well-designed accelerators are vital for advancing promising therapeutic candidates.
• A combination of funding, scientific support, and addressing cultural gaps is essential for success.